#MSVirtual2020 – Masitinib Delays Disability Progression in PPMS, Non-active SPMS
AB Science’s lead candidate masitinib safely and effectively delays disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS), according to top-line data from a clinical trial. The therapy was found to significantly lower the risk of first and confirmed (three-month) disability progression, and to reduce…